Longitudinal loop diuretic use in patients with HFrEF initiated with sodium-glucose cotransporter 2 inhibitors [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂起始治疗后心脏功能射血分数降低的患者纵向利尿剂使用情况
Daniela Tomasoni,Lina Benson,Javed Butler et al.
Daniela Tomasoni et al.
Aims: a reduction in loop diuretics need after sodium-glucose cotransporter-2 inhibitors (SGLT2i) initiation has been suggested by retrospective analyses of clinical trials. We aimed to investigate long-term changes in lo...
When Randomization Is Not Enough: Divergent Beta-Blocker Trials and the Illusion of Universal Causality [0.03%]
随机对照试验的局限性——β受体阻滞剂疗效研究引发的再思考
Elmir Omerovic,Truls Råmunddal,Sandeep Jha et al.
Elmir Omerovic et al.
Two contemporary randomized trials of β-blocker therapy after myocardial infarction (MI) reached apparently conflicting conclusions. REBOOT, conducted in Spain and Italy, found no reduction in death or major cardiovascular events among pat...
Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction? [0.03%]
静脉血管药理学：它如何有助于射血分数保留的心力衰竭？
Justin Lineham,Misha Dagan,Bing Wang et al.
Justin Lineham et al.
Heart failure with preserved ejection fraction (HFpEF) is a major cause of cardiovascular morbidity and mortality globally. Despite significant research, the pathophysiological mechanisms underlying this complex condition remain poorly defi...
Bianca Rocca
Bianca Rocca
Central figureConceptual model of the journal’s editorial and scientific ecosystem around its core principles.
The win ratio: a valuable addition to the toolbox of cardiovascular trialists [0.03%]
胜率：心血管试验研究者工具箱中的有效补充指标
Morten Wang Fagerland
Morten Wang Fagerland
Kidney function and acid-base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial [0.03%]
肾脏功能和酸碱状态作为慢性心力衰竭患者钠尿和利尿反应的调节因素：DEA-HF临床试验的新见解
Ina Volis,Amit Gruber,Aharon Ronnie Abbo et al.
Ina Volis et al.
Aims: In chronic heart failure (HF), decongestion is hindered by reduced renal function and diuretic resistance. This study compared the effect of eGFR and serum bicarbonate on three diuretic regimens in congestion-refrac...
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Patients Undergoing PCI on Dual Antiplatelet Therapy: A Retrospective Cohort Study [0.03%]
选择性血清素再摄取抑制剂对接受双重抗血小板治疗的经皮冠状动脉介入患者出血风险的影响：回顾性队列研究
Ishmum Chowdhury,Kuan-Yu Chi,Yu Chang et al.
Ishmum Chowdhury et al.
Background: Mood disorders are highly prevalent among patients with coronary artery disease, yet pharmacologic treatment with selective serotonin reuptake inhibitors (SSRIs) poses potential bleeding concerns, particularly...
Effectiveness and Safety of SGLT2 Inhibitor Initiation in Sacubitril-Valsartan Users with Heart Failure: A Population-Based Cohort Study [0.03%]
启动钠葡萄糖共转运体-2抑制剂在使用沙库必曲缬沙坦的心力衰竭患者中的有效性和安全性：基于人群的队列研究
Che-Yuan Wu,Baiju R Shah,Justin A Ezekowitz et al.
Che-Yuan Wu et al.
Background: Large-scale real-world evidence regarding outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) initiation added to sacubitril-valsartan is currently limited. We aim to investigate effectiveness and s...
Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure [0.03%]
合并症患者的血脂管理——面临的挑战：心力衰竭
Heinz Drexel,Matthias Frick,Andreas Zirlik et al.
Heinz Drexel et al.
The combined prevalence of heart failure (HF) with coronary atherosclerosis is frequent and often causally linked. The aim of this review is to elucidate whether lipid lowering drugs (LLDs) are useful in this context. The role of LLDs is in...